Synergism of Cytotoxic Effects of Vinorelbine and Paclitaxel in Vitro

References

• DeVita V TJ, Hubbard S M. Hodgkin's disease. N Engl J Med 1993; 328: 560–565
   PubMed Web of Science ®Google Scholar
• Gessner P K. Isobolographic analysis of interactions: an update on applications and utility. Toxicology 1995; 105: 161–179
   PubMed Web of Science ®Google Scholar
• Greco W R, Bravo G, Parsons J C. The search for synergy: a critical review from a response surface perspective. Pharm Rev 1995; 47: 331–385
   PubMed Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxic assays. J Immunol Methods 1983; 65: 55–63
   PubMed Web of Science ®Google Scholar
• Chen S F, Behrens C H, Czerniak P M, et al. XB596, a promising bis-naphthalimide anti-cancer agent. Anti-Cancer Drugs 1993; 4: 447–457
   PubMed Web of Science ®Google Scholar
• Kirshenbaum M R, Chen S F, Behrens C H, et al. (R,R)-2,2′-[l,2-ethanediyIbis-[imino(l-methyl-2,l-ethanediyl)]] -bis [5-nitro-lH-ben[de-isoquinoline- 1,3–(2H)-dione] dimethanesulfonate (DMP 840), a novel bis- naphthalimide with potent nonselective tumoricidal activity in vitro. Cancer Res 1994; 54: 2199–2206
   PubMed Web of Science ®Google Scholar
• MacDonald J R, Muscoplat C C, Dexter D L, et al. Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin Illudin S. Cancer Res 1997; 57: 279–283
   PubMed Web of Science ®Google Scholar
• Chou T C, Talalay P. Quantitative analysis of dose effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27–55
   PubMedGoogle Scholar
• Chou T C, Talalay P. Generalized equations for the analysis of inhibitions of Michaelis-Menton and higher order kinetic systems with two or more mutually exclusive and non-exclusive inhibitors. Eur J Biochem 1988; 115: 207–216
   Google Scholar
• Chou J, Chou T C. Dose-Effect Analysis with Microcomputers: Quantitation of ED50, LD50. Synergism, Antagonism, Low Dose Risk, Receptor-Ligand Binding, and Enzyme Kinetics. Biosoft, CambridgeUK 1987
   Google Scholar
• Wilson J K, Sargent J M, Elgie A W, et al. A feasibility study of the MTT assay for chemosensitivity testing in ovarian malignancy. Br J Cancer 1990; 62: 189–194
   PubMed Web of Science ®Google Scholar
• Park J-G, Kramer B S, Steinberg S M, et al. Chemosensitivity testing of human colorectal carcinoma cell lines using a tetrazoliumbased colorimetric assay. Cancer Res 1987; 47: 5875–5879
   PubMed Web of Science ®Google Scholar
• Kreis W, Budman D R, Calabro A. Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Br J Urol 1997; 79: 196–202
   PubMedGoogle Scholar
• Budman D R. New vinca alkaloids and related compounds. Semin Oncol 1992; 19: 639–645
   PubMed Web of Science ®Google Scholar
• Budman D R, Lichtman S M. Investigational drugs. The Chemotherapy Sourcebook, 2nd ed., M C Perry. Williams & Wilkins, Baltimore 1996; 479–558
   Google Scholar
• Haldar S, Basu A, Croce C M. Bc 12 is the guardian of microtubule integrity. Cancer Res 1997; 57: 229–233
   PubMed Web of Science ®Google Scholar
• Wang L G, Xiao M L, Kreis W, et al. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 1999; 44: 335–361
   PubMedGoogle Scholar
• Blagosklonny M V, Giannakakou P, El-Deiry W S, et al. Raf-1/ bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res 1997; 57: 130–135
   PubMed Web of Science ®Google Scholar
• Smith G A. Current status of vinorelbine for breast cancer. Oncology 1995; 9: 767–773
   PubMedGoogle Scholar
• Adams D J. Synergy of navelbine-taxol combination treatment in two human breast cancer cell lines. Proc Am Assoc Cancer Res 1994; 35: 1944a
   Google Scholar
• Knick V C, Eberwein D J, Miller C G. Vinorelbine tartrate and paclitaxel combinations: enhanced activity against in vivo P388 murine leukemia cells. J Natl Cancer Inst 1995; 87: 1072–1077
   PubMed Web of Science ®Google Scholar
• Photiou A, Shah P, Leong L K, et al. In vitro synergy of paclitaxel (Taxol) and vinorelbine (Navelbine) against human melanoma lines. Eur J Cancer 1997; 33: 463–470
   PubMed Web of Science ®Google Scholar
• Wang L G, Liu X M, Kreis W, et al. Activation of MAP kinase during apoptosis mediated by vinorelbine in MCF-7 cells. Proc Am Assoc Cancer Res 1999; 40: 89a
   Google Scholar
• Livingston R B, Ellis G K, Gralow J R, et al. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1997; 15: 1395–1400
   PubMed Web of Science ®Google Scholar
• Chang A Y, Garrow G C. Pilot study of vinorelbine (Navelbine) and paclitaxel (Taxol) in patients with refractory breast cancer and lung cancer. Semin Oncol 1995; 22: 66–70
   PubMed Web of Science ®Google Scholar
• Chang A Y, DeVore R, Johnson D. Pilot study of vinorelbine (navelbine) and paclitaxel in patients with refractory non-small cell lung cancer. Semin Oncol 1996; 23: 19–21
   PubMed Web of Science ®Google Scholar
• Ibrahim N, Hortobagyi G N, Valero V, et al. Phase I study of vinorelbine (NVB; navelbine) and paclitaxel (PTX) by simultaneous (sim) 3-hr infusion (inf) for untreated metastatic breast cancer (MBC). Proc Am Assoc Cancer Res 1995; 36: 1443a
   Google Scholar
• Dieras V., Fumoleau P, Bourgeois H, et al. Taxoids in combination chemotherapy for metastatic breast cancer. Anti-Cancer Drugs 1996; 7: 47–52
   PubMed Web of Science ®Google Scholar
• Michelotti A, Gennari A, Salvadorl B, et al. Paclitaxel and vinorelbine in anthracycline-pretreated breast cancer: A phase II study. Ann Oncol 1996; 7: 857–860
   PubMed Web of Science ®Google Scholar
• Weiselberg L, Budman D R, O'Mara V, et al. Phase I trial of sequential vinorelbine-paclitaxel in patients with metastatic breast cancer: early evidence of tolerability and efficacy. Proc Am Soc Clin Oncol 1996; 32: 54a
   Google Scholar
• Tortoriello A., Facchini G, Caponigro F., et al. Phase I/II study of paclitaxel and vinorelbine in metastatic breast cancer. Breast Cancer Res Treat 1998; 47: 91–97
   PubMed Web of Science ®Google Scholar
• Iaffaioli R V, Facchini G., Tortoriello A., et al. Phase I study of vinorelbine and paclitaxel in small-cell lung cancer. Cancer Chemother Pharmacol 1997; 41: 86–90
   PubMed Web of Science ®Google Scholar
• Retsas S, Mohith A, Mackenzie H. Taxol and vinorelbine: a new active combination for disseminated melanoma. Anti-Cancer Drugs 1996; 7: 161–165
   PubMed Web of Science ®Google Scholar
• Acuna L R, Langhi M., Perez J., et al. Vinorelbine and paclitaxel as first-line chemotherapy in metastatic breast cancer. J Clin Oncol 1999; 17: 74–81
   PubMed Web of Science ®Google Scholar
• Budman D R, Calabro A, Stiel L, et al. In vitro studies of paclitaxel in combination with either etoposide or vinorelbine: sequence dependent effects causing synergism or antagonism. Proc Am Assoc Cancer Res 1996; 37: 2493a
   Google Scholar
• Scuiero D., Monks A. A., Sausville E A. Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen. J Natl Cancer Inst 1998; 90: 862
   Web of Science ®Google Scholar
• Kreis W, Budman D R, Broome J., et al. Evaluation of three established cell lines derived from patients with prostate cancer (DU 145, PC-3. LnCaP) for phenotype and sensitivity to doxorubicin and vinblastine with or without the new cyclosporin D derivative PSC 833. Cell Pharmacol 1995; 2: 229–235
   Google Scholar
• Chen T R. In situ detection of Mycoplaama contamination in cell cultures by fluorescent Hoechst 33258 stain. Exp Cell Res 1977; 104: 255–262
   PubMed Web of Science ®Google Scholar
• Photiou Sheikh A. M, Bafaloukos N. D., et al. Antiproliferative activity of vinorelbine (navelbine) against six human melanoma cell lines. J Cancer Res Clin Oncol 1992; 118: 249–254
   PubMed Web of Science ®Google Scholar
• Raymond E, Hanauske A., Faivre S., et al. Effects of prolonged versus short-term exposure paclitaxel (Taxol) on human tumor colony-forming units. Anti-Cancer Drugs 1997; 8: 379–385
   PubMed Web of Science ®Google Scholar
• Cahan M A, Walter K A, Colvin O M, et al. Cytotoxicity of taxol in vitro against human and rat malignant brain tumors. Cancer Chemother Pharmacol 1994; 33: 441–444
   PubMed Web of Science ®Google Scholar
• Rowinsky E., Donehower K. R, Jones C. RJ., et al. Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res 1988; 48: 4093–5000
   PubMed Web of Science ®Google Scholar
• RiccardiServidei A. T., Tornesello A., et al. Cytotoxicity of paclitaxel and docetaxel in human neuroblastoma cell lines. Eur J Cancer 1995; 31: 494–499
   Google Scholar
• Twentyman P., Luscombe R. M. A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer 1987; 56: 279–286
   PubMed Web of Science ®Google Scholar
• Rubinstein L., Shoemaker V. R, Paull H. KD., et al. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 1990; 82: 1113–1118
   PubMed Web of Science ®Google Scholar
• Chang DeVore A., Gu R. C, et al. Paclitaxel and vinorelbine in advanced non-small cell lung cancer: in vitro and clinical studies. Proc Am Assoc Cancer Res 1996; 37: 1158a
   Google Scholar